Please login to the form below

Not currently logged in

Lilly planning 20 new launches by 2023

Will focus on diabetes, immunology, oncology, neurodegeneration and pain
Eli Lilly

Eli Lilly is heading into the most prolific period in its 140-year history for new product launches, according to chief executive John Lechleiter.

The US pharma company is hoping to launch 20 new molecular entities (NMEs) in the 2014 to 2023 timeframe, backed up by two new indications or line extensions each year, across its core therapeutic categories of diabetes, immunology, oncology, neurodegeneration and pain.

Lechleiter noted that Lilly has launched six new products in the last two years alone - including Cyramza (ramucirumab), diabetes therapies Jardiance (empagliflozin) and Trulicity (dulaglutide) and most recently Taltz (ixekizumab) for psoriasis.

The company said that its R&D efforts in diabetes are aimed at the development of differentiated therapeutics and delivery devices within "glucose control, metabolic control and end-organ protection". 

The company has high hopes for its phase II PCSK9 inhibitor - suggesting it could offer less frequent dosing than the two approved drugs in this class, Sanofi/Regeneron's Praluent (alirocumab) and Amgen's Repatha (evolocumab). It also highlighted nasal glucagon - currently in phase III - and GLP-1 agonist/glucagon combinations.

Turning to oncology, Lilly said it is focusing on tumour cell signalling, tumour microenvironment and immuno-oncology.

Top projects include PDGF inhibitor olaratumab, which was granted priority review by the FDA earlier this month for soft tissue sarcoma, and CDK4/6 inhibitor abemaciclib for advanced breast cancer and mantle cell lymphoma. Olaratumab will see its first marketing applications later this year, with abemaciclib filings due to start in 2017.

Meanwhile, Lilly said that its immuno-oncology portfolio will have as many as 11 molecules in clinical development by the end of 2018, including five due to start trials this year.

Lilly's neuroscience R&D portfolio is headed by its Alzheimer's disease (AD) programmes, which include seven candidates headed by AstraZeneca-partnered BACE inhibitor AZD3293, and has recently started phase III trials.

In immunology, Lilly highlighted the recent filing of oral rheumatoid arthritis therapy baricitinib, armed with data showing it is more effective than market-leading, injectable TNF inhibitor Humira (adalimumab) from AbbVie.

The selective JAK1 and JAK2 inhibitor is being co-developed with Incyte and heads up "a robust emerging pipeline of both internal assets and partnered molecules focusing on key pathways and interventions in multiple autoimmune diseases."

Meanwhile, Taltz' approval in psoriasis is being followed by trials in psoriatic arthritis and axial spondylitis as the company tries to catch up with Novartis which was first to market with rival IL-17 inhibitor Cosentyx (secukinumab).

In pain control - which Lilly views as an emerging R&D focus - the company highlighted galcanezumab, potentially a first-in-class CGRP inhibitor for cluster headache and migraine, as well as Pfizer-partnered NGF inhibitor tanezumab for osteoarthritis pain, chronic lower back pain and cancer pain. Both are currently in phase III testing.

"We have improved the productivity and success of our pipeline through discrete actions aimed at enhancing focus, quality and speed, and by positioning ourselves as an attractive partner for external innovation opportunities," commented Jan Lundberg, president of Lilly Research Laboratories.

"These improvements have led to the potential for unprecedented R&D output."

Article by
Phil Taylor

26th May 2016

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

How ‘Greenwashing’ accusations could delay the very changes its supporters demand
Are shouts of companies ‘greenwashing’ to provide a façade of environmental and ethical respectability causing more harm than good? Or should we call out practices that we believe are papering...
What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...